Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 03, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted Corrina Pavetto, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 10,275 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of June 28, 2024. The stock option has an exercise price of $11.94 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date that occurs during the calendar quarter that includes the Date of Grant. Quarterly Vesting Date means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of Cidara's 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder.
2024年7月3日聖地亞哥。生物技術公司Cidara Therapeutics, Inc. (納斯達克:CDTX) 使用其專有的Cloudbreak平台開發藥物-Fc偶聯物(DFC)免疫療法，旨在挽救生命並改善面臨嚴重疾病的患者的標準醫療護理。今天宣佈，公司董事會的薪酬委員會根據Cidara Therapeutics, Inc. 2020年引誘激勵計劃授予新員工Corrina Pavetto非限定性股票期權及受限制的股票單位(RSUs)，總計10,275股普通股，則授予日期爲2024年6月28日。股票期權的行使價格爲每股11.94美元，等於Cidara普通股授予日收盤價。該期權股份將分四年歸屬，其中25%的股票將於歸屬起始日一週年紀念日歸屬，其餘股票將分36個連續相等月分期支付並歸屬。所有RSUs按照四個平均年分期付款，其中1/4的RSUs將在包括授予日期的日曆季度內的第一個、第二個、第三個和第四個週年紀念日分別歸屬。季度歸屬日期是每年的3月10日、6月10日、9月10日或12月10日。授予取決於授予獲得者在每個歸屬日期的持續服務以及Cidara的2020年引誘激勵計劃和其標準授予協議的條款和條件。
The foregoing equity award was granted as an inducement material to the employee entering into employment with Cidara, in accordance with Nasdaq Listing Rule 5635(c)(4). The Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Cidara, or following a bona fide period of non-employment, as an inducement material to such individual's entering into employment with Cidara, pursuant to Nasdaq Listing Rule 5635(c)(4).
該股權獎勵是根據納斯達克規定5635（c）（4）對降低員工加入門檻而授予的，Cidara Therapeutics公司的2020年誘因激勵計劃專門用於向之前不是Cidara員工的個人授予股權激勵，或在較長且真實的非就業期之後，爲了降低個人加入Cidara員工的門檻而授予。
About Cidara Therapeutics
cidara therapeutics簡介
Cidara Therapeutics is using its proprietary Cloudbreak platform to develop novel drug-Fc conjugates (DFCs). These targeted immunotherapies offer the unique opportunity to create "single molecule cocktails" comprised of targeted small molecules and peptides coupled to a human antibody fragment (Fc). DFCs are designed to save lives and improve the standard of care for patients facing serious diseases by inhibiting specific disease targets while simultaneously engaging the immune system. Cidara is headquartered in San Diego, California. For more information, please visit .
Cidara Therapeutics正在使用其專有的Cloudbreak平台開發新型藥物-Fc偶聯物(DFCs)。這些有針對性的免疫療法提供了創造 "單分子雞尾酒"的獨特機會，由針對性的小分子和肽耦合到人源抗體片段(Fc)中。DFCs旨在通過在抑制特定疾病靶點的同時與免疫系統相互作用，挽救生命和改善面臨嚴重疾病的患者的醫療護理標準。Cidara總部位於加利福尼亞州聖地亞哥。欲了解更多信息，請訪問網站。
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
投資者聯繫方式：
Brian Ritchie
LifeSci Advisors
（212）915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
媒體聯繫人：
Michael Fitzhugh
通信-半導體
mfitzhugh@lifescicomms.com
